Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt, Cairo, Egypt; Department of Pharmaceutical Technology, Pharmaceutical and Drug Industries Research Division, National Research Center, Dokki, Cairo, Egypt.
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, Egypt.
Eur J Pharm Sci. 2018 Sep 15;122:64-76. doi: 10.1016/j.ejps.2018.06.015. Epub 2018 Jun 19.
Roflumilast is a selective inhibitor of phosphodiesterase-4 isoenzyme in lung cells. Having psychiatric adverse reactions when administered orally affects negatively the patients' adherence to the drug. This work aimed to prepare emulsified spray dried alginate microparticles for the pulmonary delivery of roflumilast. Sodium alginate was used as microparticle-forming material, isopropyl myristate as an oil, Tween®80 as surfactant and calcium beta-glycerophosphate as cross-linking agent to enhance the mechanical properties of the particles. The prepared particles were evaluated for their encapsulation efficiency, particle size and in-vitro drug release. From the studied carriers, beta-cyclodextrin (CD) was the best regarding giving formulation with smaller particle size and more sustained drug release. The inhalation profile of CD-based microparticles was investigated using Anderson cascade impactor. The aerosolization profile of CD-based microparticles suggested their efficiency to deliver the drug deep in the lung. The CD-based microparticles possessed more inhibitory effects on the viability of A549 cells and on the pro-inflammatory cytokines (TNF-α, IL-6 and IL-10) compared to the pure drug. Hence, CD-based microparticles could regulate the tumorigenesis besides tumor-associated inflammation. Finally, CD-based microparticles showed more sustained bronchodilatation properties in healthy human volunteers when compared to Ventolin®HFA. CD-based microparticles proved to be a promising carrier for inhaled roflumilast in human.
罗氟司特是一种肺细胞内磷酸二酯酶-4 同工酶的选择性抑制剂。口服时有精神不良反应会对患者对药物的依从性产生负面影响。本工作旨在制备包封罗氟司特的乳化喷雾干燥海藻酸钠微球。海藻酸钠用作微球形成材料,肉豆蔻异丙酯用作油,吐温®80 用作表面活性剂,β-甘油磷酸钙用作交联剂,以增强颗粒的机械性能。对制备的颗粒进行包封效率、粒径和体外药物释放的评价。在所研究的载体中,β-环糊精(CD)在形成粒径更小、药物释放更持续的制剂方面表现最佳。使用安德森级联撞击器研究了基于 CD 的微球的吸入特性。基于 CD 的微球的气溶胶化特性表明,它们能够有效地将药物输送到肺部深处。与纯药物相比,基于 CD 的微球对 A549 细胞活力和促炎细胞因子(TNF-α、IL-6 和 IL-10)具有更强的抑制作用。因此,CD 基微球除了调节肿瘤相关炎症外,还可以调节肿瘤发生。最后,与 Ventolin®HFA 相比,基于 CD 的微球在健康人体志愿者中显示出更持久的支气管扩张作用。基于 CD 的微球被证明是一种有前途的人用罗氟司特吸入载体。